Nemaura Medical Appoints Jay L. Warner as Head of U.S. Commercial Operations
February 01 2021 - 8:00AM
Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”),
a medical technology company focused on developing and
commercializing non-invasive wearable diagnostic devices and
supporting personalized lifestyle coaching programs, today
announces the appointment of Jay L. Warner, a 30-year veteran of
the healthcare industry, as head of U.S. commercial operations.
“Jay brings a wealth of experience to Nemaura,
including his experience in developing and commercializing wearable
devices applicable to the diabetes market. He has spent a
significant portion of his career in that market, providing a solid
understanding of the specific needs associated with wearable
devices. In addition, he brings the strong relationships that he
has built with U.S.-based insurers, which we believe will help to
drive the company’s success,” said Faz Chowdhury, Ph.D., Nemaura’s
CEO. “We are at an important inflection point of the company, as
telemedicine platforms such as Livongo and app-based wellness have
become more and more ubiquitous since the advent of COVID-19.
However, fewer than one million of the more than 25 million people
with diabetes are being adequately managed utilizing such services,
providing an important and significant opportunity for our
clinically proven program, BEATdiabetes.life to not only impact
those lives, but 90 million pre-diabetics, the majority of whom may
not have adequate support.”
Prior to joining Nemaura, Mr. Warner served as
senior vice president of clinical and commercialization at Cequr
Corporation, where he oversaw the clinical development and
commercialization of two three-day wearable insulin delivery
devices. He also spent 17 years at Eli Lilly in increased levels of
responsibility, working as U.S. Brand Leader for Byetta, U.S. and
global endocrine director of market research, among other roles.
Mr. Warner holds an M.B.A. from Boston University and a Bachelor of
Science degree in marketing from Miami University, Oxford, Oh.
“Nemaura is a truly unique company that has
utilized more than 12 years of clinical evidence to create a
user-friendly, measurable approach to managing diabetes that
integrates both behavioral modification and a wearable, disposable
device that allows the impact of glucose trends to be utilized in
diabetes management in a flexible and cost-efficient manner. I’m
looking forward to collaborating with the team to make the
BEATdiabetes program a success in the United States market,” added
Mr. Warner.
About Nemaura Medical, Inc.
Nemaura Medical Inc. is a medical technology
company developing and commercializing non-invasive wearable
diagnostic devices. The company is currently commercializing
sugarBEAT® and proBEAT™. sugarBEAT®, a CE mark approved Class IIb
medical device, is a non-invasive and flexible continuous glucose
monitor (CGM) providing actionable insights derived from real time
glucose measurements and daily glucose trend data, which may help
people with diabetes and pre-diabetes to better manage, reverse,
and prevent the onset of diabetes. Nemaura has submitted a PMA
(Premarket Approval Application) for sugarBEAT® to the U.S. FDA.
proBEAT™ combines non-invasive glucose data processed using
artificial intelligence and a digital healthcare subscription
service and is expected to be launched in the U.S. as a general
wellness product.
The Company sits at the intersection of the
global Type 2 diabetes market that is expected to reach nearly $59
billion by 2025, the $50+ billion pre-diabetic market, and the
wearable health-tech sector for weight loss and wellness
applications that is estimated to reach $60 billion by 2023.
For more information, please visit
www.NemauraMedical.com.
Cautionary Statement Regarding
Forward-Looking Statements:
The statements in this press release that are
not historical facts may constitute forward-looking statements that
are based on current expectations and are subject to risks and
uncertainties that could cause actual future results to differ
materially from those expressed or implied by such statements.
Those risks and uncertainties include, but are not limited to, the
launch of proBEAT™ in the US, risks related to regulatory status
and the failure of future development and preliminary marketing
efforts, Nemaura’s ability to secure additional commercial
partnering arrangements, risks and uncertainties relating to
Nemaura and its partners’ ability to develop, market and sell
proBEAT™, the availability of substantial additional equity or debt
capital to support its research, development and product
commercialization activities, and the success of its research,
development, regulatory approval, marketing and distribution plans
and strategies, including those plans and strategies related to
both proBEAT™ digital health, and sugarBEAT®. There can be no
assurance that the company will be able to reach a part of or any
of the global market for CGM with its products/services. The FDA
reserves the right to re-evaluate their decision that proBEAT™
qualifies as a general wellness product should it become aware of
any issues such as skin irritation or other adverse events from the
device, as well as any misuse impacting patient safety, and any
other reason as the FDA may see fit at its discretion to determine
the product does not fit the definition of a general wellness
product. These and other risks and uncertainties are identified and
described in more detail in Nemaura’s filings with the United
States Securities and Exchange Commission, including, without
limitation, its Annual Report on Form 10-K for the most recently
completed fiscal year, its Quarterly Reports on Form 10-Q, and its
Current Reports on Form 8-K. Nemaura undertakes no obligation to
publicly update or revise any forward-looking statements.
Contact:
Jules AbrahamCORE
IR917-885-7378julesa@coreir.com
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nemaura Medical (NASDAQ:NMRD)
Historical Stock Chart
From Apr 2023 to Apr 2024